AstraZeneca PLC ADR (AZN): Price and Financial Metrics

AstraZeneca PLC ADR (AZN): $69.46

0.26 (+0.38%)

POWR Rating

Component Grades














  • Sentiment is the dimension where AZN ranks best; there it ranks ahead of 93.37% of US stocks.
  • The strongest trend for AZN is in Stability, which has been heading up over the past 177 days.
  • AZN ranks lowest in Momentum; there it ranks in the 7th percentile.

AZN Stock Summary

  • AZN has a market capitalization of $210,493,840,075 -- more than approximately 99.27% of US stocks.
  • With a price/earnings ratio of 64.02, ASTRAZENECA PLC P/E ratio is greater than that of about 91.66% of stocks in our set with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, ASTRAZENECA PLC is reporting a growth rate of 272.29%; that's higher than 94.53% of US stocks.
  • Stocks that are quantitatively similar to AZN, based on their financial statements, market capitalization, and price volatility, are PFE, CSCO, NVS, BABA, and ADBE.
  • Visit AZN's SEC page to see the company's official filings. To visit the company's web site, go to

AZN Valuation Summary

  • AZN's EV/EBIT ratio is 60.8; this is 821.21% higher than that of the median Healthcare stock.
  • Over the past 243 months, AZN's price/earnings ratio has gone up 42.7.

Below are key valuation metrics over time for AZN.

Stock Date P/S P/B P/E EV/EBIT
AZN 2023-03-24 4.7 5.7 64.0 60.8
AZN 2023-03-23 4.7 5.6 63.4 60.3
AZN 2023-03-22 4.7 5.6 62.8 59.7
AZN 2023-03-21 4.7 5.6 63.2 60.0
AZN 2023-03-20 4.7 5.6 62.9 59.8
AZN 2023-03-17 4.6 5.5 61.9 58.9

AZN Growth Metrics

    Its 3 year price growth rate is now at 74.78%.
  • Its 3 year cash and equivalents growth rate is now at 39.31%.
  • The 2 year cash and equivalents growth rate now stands at 68.83%.
Over the past 70 months, AZN's revenue has gone up $22,059,000,000.

The table below shows AZN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 44,351 9,808 3,288
2022-12-31 44,351 9,808 3,288
2022-09-30 45,154 8,828 2,039
2022-06-30 44,038 7,617 -1,253
2022-03-31 41,487 7,261 -1,063
2021-12-31 37,417 5,963 112

AZN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AZN has a Quality Grade of B, ranking ahead of 78.56% of graded US stocks.
  • AZN's asset turnover comes in at 0.438 -- ranking 104th of 681 Pharmaceutical Products stocks.
  • CLVS, HSKA, and FLXN are the stocks whose asset turnover ratios are most correlated with AZN.

The table below shows AZN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.438 0.765 0.209
2021-03-31 0.431 0.792 0.231
2020-12-31 0.429 0.801 0.205
2020-09-30 0.427 0.801 0.174
2020-06-30 0.433 0.800 0.161
2020-03-31 0.422 0.794 0.126

AZN Stock Price Chart Interactive Chart >

Price chart for AZN

AZN Price/Volume Stats

Current price $69.46 52-week high $72.12
Prev. close $69.20 52-week low $52.65
Day low $69.42 Volume 1,513,892
Day high $69.93 Avg. volume 5,119,853
50-day MA $66.50 Dividend yield 2.81%
200-day MA $64.43 Market Cap 215.30B

AstraZeneca PLC ADR (AZN) Company Bio

AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Latest News Stream

Event/Time News Detail
Loading, please wait...

AZN Latest Social Stream

Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about ASTRAZENECA PLC that investors may wish to consider to help them evaluate AZN as an investment opportunity.

Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) reported Q4 earnings and provided updates across its pipeline. The investors are reacting to the further pushback of the timeline for the readout from the Phase 2a study of elarekibep to mid-2024 from prior guidance of the third quarter of 2023. Pieris is collaborating with AstraZeneca Plc (NASDAQ: AZN) to develop elarekibep for asthma patients. AstraZeneca has communicated that completion of the Phase 2a study remains an important priority and that addi

Yahoo | March 29, 2023

AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review

Ionis Pharmaceuticals Inc (NASDAQ: IONS) released topline results from the 66-week analysis of Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca Plc's (NASDAQ: AZN) eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) that leads to peripheral nerve damage and motor disability. At 66 weeks, patients treated with eplontersen demonstrated a statistically significant and clinically meaningful change from baseline versus an external placebo group on t

Yahoo | March 27, 2023

Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study

Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

Yahoo | March 27, 2023

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

WILMINGTON, Del., March 27, 2023--Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022.1

Yahoo | March 27, 2023

Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%

Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.

Yahoo | March 24, 2023

Read More 'AZN' Stories Here

AZN Price Returns

1-mo 6.52%
3-mo 3.90%
6-mo 28.46%
1-year 6.93%
3-year 67.04%
5-year 127.26%
YTD 3.90%
2022 19.10%
2021 19.66%
2020 3.06%
2019 35.58%
2018 13.77%

AZN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6604 seconds.